Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 7/2016

18.01.2016 | Original Article

Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes

verfasst von: Nathalie L. Albert, Marcus Unterrainer, Markus Diemling, Guoming Xiong, Peter Bartenstein, Walter Koch, Andrea Varrone, John C. Dickson, Livia Tossici-Bolt, Terez Sera, Susanne Asenbaum, Jan Booij, L. Özlem Atay Kapucu, Andreas Kluge, Morten Ziebell, Jacques Darcourt, Flavio Nobili, Marco Pagani, Osama Sabri, Swen Hesse, Thierry Vander Borght, Koen Van Laere, Klaus Tatsch, Christian la Fougère

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Even though [123I]FP-CIT SPECT provides high accuracy in detecting nigrostriatal cell loss in neurodegenerative parkinsonian syndromes (PS), some patients with an inconclusive diagnosis remain. We investigated whether the diagnostic accuracy in patients with clinically uncertain PS with previously inconclusive findings can be improved by the use of iterative reconstruction algorithms and an improved semiquantitative evaluation which additionally implemented a correction algorithm for patient age and gamma camera dependency (EARL-BRASS; Hermes Medical Solutions, Sweden).

Methods

We identified 101 patients with inconclusive findings who underwent an [123I]FP-CIT SPECT between 2003 and 2010 as part of the diagnostic process of suspected PS at the University of Munich, and re-evaluated these scans using iterative reconstruction algorithms and the new corrected EARL-BRASS. Clinical follow-up was obtained in 62 out of the 101 patients and constituted the gold standard for the re-evaluation to assess the possible improvement in diagnostic accuracy.

Results

Clinical follow-up confirmed the diagnosis of PS in 11 of the 62 patients. In patients in whom both visual and semiquantitative analysis showed concordant findings (48 patients), a high negative predictive value (93 %), positive predictive value (100 %) and accuracy (94 %) were found, and thus a correct diagnosis was obtained in 45 of the 48 patients. Among the 14 patients with discordant findings, the additional semiquantitative analysis correctly identified all five of nine patients patients without PS by nonpathological semiquantitative findings in visually pathological or inconclusive scans. In contrast, four of the remaining five patients with decreased semiquantitative values but visually normal scans did not show a PS during follow-up.

Conclusion

The age-corrected and camera-corrected mode of evaluation using EARL-BRASS provided a notable improvement in the diagnostic accuracy of [123I]FP-CIT SPECT in PS patients with previously inconclusive findings. The gain in accuracy might be achieved by better discrimination between physiological low striatal [123I]FP-CIT binding due to age-related loss of the dopamine transporter or pathological loss of binding.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res. 2015;5:12. doi:10.1186/s13550-015-0087-1.CrossRefPubMedPubMedCentral Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res. 2015;5:12. doi:10.​1186/​s13550-015-0087-1.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Darcourt J, Booij J, Tatsch K, Varrone A, Borght T, Kapucu Ö, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–50. doi:10.1007/s00259-009-1267-x.CrossRefPubMed Darcourt J, Booij J, Tatsch K, Varrone A, Borght T, Kapucu Ö, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443–50. doi:10.​1007/​s00259-009-1267-x.CrossRefPubMed
4.
Zurück zum Zitat McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13. doi:10.1016/S1474-4422(07)70057-1.CrossRefPubMed McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13. doi:10.​1016/​S1474-4422(07)70057-1.CrossRefPubMed
5.
Zurück zum Zitat Booij J, Speelman J, Horstink MIM, Wolters E. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266–72. doi:10.1007/s002590000460.CrossRefPubMed Booij J, Speelman J, Horstink MIM, Wolters E. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266–72. doi:10.​1007/​s002590000460.CrossRefPubMed
6.
7.
Zurück zum Zitat Hughes AJ, Daniel SE, Ben‐Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861–70.CrossRefPubMed Hughes AJ, Daniel SE, Ben‐Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861–70.CrossRefPubMed
8.
Zurück zum Zitat Plotkin M, Amthauer H, Klaffke S, Kühn A, Lüdemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm. 2005;112:677–92. doi:10.1007/s00702-004-0208-x.CrossRefPubMed Plotkin M, Amthauer H, Klaffke S, Kühn A, Lüdemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm. 2005;112:677–92. doi:10.​1007/​s00702-004-0208-x.CrossRefPubMed
9.
Zurück zum Zitat Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord. 2004;19:1175–82. doi:10.1002/mds.20112.CrossRefPubMed Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord. 2004;19:1175–82. doi:10.​1002/​mds.​20112.CrossRefPubMed
10.
Zurück zum Zitat Tolosa E, Borght TV, Moreno E. Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007;22:2346–51. doi:10.1002/mds.21710.CrossRefPubMed Tolosa E, Borght TV, Moreno E. Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007;22:2346–51. doi:10.​1002/​mds.​21710.CrossRefPubMed
11.
Zurück zum Zitat Varrone A, Dickson J, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40:213–27. doi:10.1007/s00259-012-2276-8.CrossRefPubMed Varrone A, Dickson J, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40:213–27. doi:10.​1007/​s00259-012-2276-8.CrossRefPubMed
12.
Zurück zum Zitat Koch W, Pogarell O, Pöpperl G, Hornung J, Hamann C, Gildehaus F-J, et al. Extended studies of the striatal uptake of 99mTc-NC100697 in healthy volunteers. J Nucl Med. 2007;48:27–34.PubMed Koch W, Pogarell O, Pöpperl G, Hornung J, Hamann C, Gildehaus F-J, et al. Extended studies of the striatal uptake of 99mTc-NC100697 in healthy volunteers. J Nucl Med. 2007;48:27–34.PubMed
13.
Zurück zum Zitat Tossici-Bolt L, Dickson JC, Sera T, de Nijs R, Bagnara MC, Jonsson C, et al. Calibration of gamma camera systems for a multicentre European [123I]-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging. 2011;38:1529–40.CrossRefPubMed Tossici-Bolt L, Dickson JC, Sera T, de Nijs R, Bagnara MC, Jonsson C, et al. Calibration of gamma camera systems for a multicentre European [123I]-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging. 2011;38:1529–40.CrossRefPubMed
14.
Zurück zum Zitat Beck AT, Ward C, Mendelson M. Beck depression inventory (BDI). Arch Gen Psychiatry. 1961;4:561–71.CrossRefPubMed Beck AT, Ward C, Mendelson M. Beck depression inventory (BDI). Arch Gen Psychiatry. 1961;4:561–71.CrossRefPubMed
15.
Zurück zum Zitat Derogatis LR, Rickels K, Rock AF. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry. 1976;128:280–9.CrossRefPubMed Derogatis LR, Rickels K, Rock AF. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry. 1976;128:280–9.CrossRefPubMed
17.
Zurück zum Zitat Koch W, Unterrainer M, Xiong G, Bartenstein P, Diemling M, Varrone A, et al. Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging. 2014;41:1938–46. doi:10.1007/s00259-014-2785-8.CrossRefPubMed Koch W, Unterrainer M, Xiong G, Bartenstein P, Diemling M, Varrone A, et al. Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging. 2014;41:1938–46. doi:10.​1007/​s00259-014-2785-8.CrossRefPubMed
18.
Zurück zum Zitat Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192–205.CrossRefPubMed Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18:192–205.CrossRefPubMed
19.
Zurück zum Zitat Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med. 2005;46:1109–18.PubMed Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med. 2005;46:1109–18.PubMed
20.
Zurück zum Zitat Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89. doi:10.1006/nimg.2001.0978.CrossRefPubMed Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89. doi:10.​1006/​nimg.​2001.​0978.CrossRefPubMed
21.
Zurück zum Zitat Mozley PD, Acton PD, Barraclough ED, Plössl K, Gur RC, Alavi A, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med. 1999;40:1812–7.PubMed Mozley PD, Acton PD, Barraclough ED, Plössl K, Gur RC, Alavi A, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med. 1999;40:1812–7.PubMed
22.
Zurück zum Zitat Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson’s disease follows a single exponential rather than linear decline. J Nucl Med. 2004;45:1694–7.PubMed Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson’s disease follows a single exponential rather than linear decline. J Nucl Med. 2004;45:1694–7.PubMed
23.
Zurück zum Zitat la Fougere C, Popperl G, Levin J, Wangler B, Boning G, Uebleis C, et al. The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med. 2010;51:581–7. doi:10.2967/jnumed.109.071811.CrossRefPubMed la Fougere C, Popperl G, Levin J, Wangler B, Boning G, Uebleis C, et al. The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med. 2010;51:581–7. doi:10.​2967/​jnumed.​109.​071811.CrossRefPubMed
24.
Zurück zum Zitat Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson’s disease: monitoring of disease progression over 2 years. Nucl Med Commun. 2001;22:721–5.CrossRefPubMed Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson’s disease: monitoring of disease progression over 2 years. Nucl Med Commun. 2001;22:721–5.CrossRefPubMed
25.
Zurück zum Zitat Marek K, Seibyl J. Beta-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-cit study: long-term imaging assessment. Neurology. 2003;60:A293. Marek K, Seibyl J. Beta-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-cit study: long-term imaging assessment. Neurology. 2003;60:A293.
26.
Zurück zum Zitat Schwingenschuh P, Ruge D, Edwards MJ, Terranova C, Katschnig P, Carrillo F, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson’s disease: a clinical and electrophysiological study. Mov Disord. 2010;25:560–9.CrossRefPubMedPubMedCentral Schwingenschuh P, Ruge D, Edwards MJ, Terranova C, Katschnig P, Carrillo F, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson’s disease: a clinical and electrophysiological study. Mov Disord. 2010;25:560–9.CrossRefPubMedPubMedCentral
Metadaten
Titel
Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes
verfasst von
Nathalie L. Albert
Marcus Unterrainer
Markus Diemling
Guoming Xiong
Peter Bartenstein
Walter Koch
Andrea Varrone
John C. Dickson
Livia Tossici-Bolt
Terez Sera
Susanne Asenbaum
Jan Booij
L. Özlem Atay Kapucu
Andreas Kluge
Morten Ziebell
Jacques Darcourt
Flavio Nobili
Marco Pagani
Osama Sabri
Swen Hesse
Thierry Vander Borght
Koen Van Laere
Klaus Tatsch
Christian la Fougère
Publikationsdatum
18.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3304-2

Weitere Artikel der Ausgabe 7/2016

European Journal of Nuclear Medicine and Molecular Imaging 7/2016 Zur Ausgabe